Schisandrin B inhibits cell growth and adherence in melanoma cancer cells

Abstract

Melanoma, a severe skin cancer, is caused by malignant melanocyte alteration. Despite advancements in therapeutics targeting mutant genes and immunological checkpoints, low response rates and resistance to current therapies hinder further advancements in melanoma management. Schisandrin B (Sch-b), a lignan compound from Schisandra, has been found to have anti-cancer effects, stopping the proliferation of cancer cells and preventing cell migration. It triggers cell cycle arrest and suppresses the many cancer cell singnalling pathways, inhibiting melanoma cells from proliferating. A2058 melanoma cancer cells were used in our study. The proliferation effect of Sch-b on A2058 melanoma cancer cells at the 72nd hour was examined by MTT. Cell adhesion properties were tested at two effective doses. A study using A2058 melanoma cancer cells showed significant anticancer effects within 72 hours of different dosages. Sch-b also prevented strong cell adherence, indicating its potential in treating melanoma.